Abstract:Purpose Cabazitaxel (CBZ) is a new taxane-based antitumor drug approved by the FDA for the treatment of prostate cancer, especially for patients with advanced prostate cancer for whom docetaxel is ineffective or causes aggravation. However, Tween 80 injection can cause serious allergic reactions, and CBZ itself has strong toxicity, adverse reactions, and poor tumor selectivity, which greatly limits its clinical applications. Therefore, the CBZ-loaded bovine serum albumin nanoparticles (CBZ-BSA-Gd-NPs) were developed to overcome the allergenic response of Tween 80 and realize the integration of diagnosis and treatment. Methods CBZ-BSA-Gd-NPs were prepared by the biomineralization method. The characterization, magnetic resonance imaging (MRI), safety, and antitumor activity of the nanoparticles were evaluated in vitro and in vivo. Results The prepared nanoparticles were uniform in size (166 nm), with good MRI performance and stability over 24 h. Compared with CBZ-Tween 80 injection, CBZ-BSA-Gd-NPs showed much lower hemolysis, similar tumor inhibition, and enhanced cellular uptake in vitro. The pharmacokinetic behavior of CBZ-BSA-Gd-NPs in rats showed that the retention time of the nanoparticles was prolonged, the clearance rate decreased, and the area under the drug-time curve increased. The distribution of CBZ-BSA-Gd-NPs in nude mice was characterized by UPLC-MS/MS and MRI, and the results showed that CBZ-BSA-Gd-NPs could effectively target tumor tissues with reduced distribution in the heart, liver, spleen, lungs, and kidneys compared with CBZ-Tween 80, which indicated that CBZ-BSA-Gd-NPs not only had a passive targeting effect on tumor tissue but also achieved the integration of diagnosis and treatment. In vivo, CBZ-BSA-Gd-NPs showed improved tumor inhibitory effect with a safer profile. Conclusion In summary, CBZ-BSA-Gd-NPs can serve as an effective therapeutic drug carrier to deliver CBZ into prostate cancer, and realize the integration of diagnosis and therapy.

Research Advances in Drug Delivery System of Cabazitaxel for Treatment of Patients with Prostate Cancer

Current development of cabazitaxel drug delivery systems

Recent progress in nanoformulations of cabazitaxel

Preparation and Evaluation of Cabazitaxel-Loaded Bovine Serum Albumin Nanoparticles for Prostate Cancer

Cabazitaxel, a Novel Chemotherapeutic Alternative for Drug-Resistant Hepatocellular Carcinoma.

The Efficacy of Cabazitaxel in Treating Prostate Cancer: A Systematic Review and Meta-Analysis

Enzyme-responsive polymeric micelles of cabazitaxel for prostate cancer targeted therapy

Transforming a Toxic Drug into an Efficacious Nanomedicine Using a Lipoprodrug Strategy for the Treatment of Patient-Derived Melanoma Xenografts.

Advances in nano-drug delivery systems for docetaxel

Taxanes prodrug-based nanomedicines for cancer therapy

Advances in the formulations of non-injection administration of docetaxel.

Research progress of paclitaxel drug delivery systems

A dual-response drug delivery system with X-ray and ROS to boost the anti-tumor efficiency of TPZ <i>via</i> enhancement of tumor hypoxia levels

Progress in Carriers of Anticancer Paclitaxel

Emerging nanotaxanes for cancer therapy

Progress of Clinical Research on New Nano-Drug Delivery System of Paclitaxel

Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy

Progress on the Prodrugs of Paclitaxel

Nanoways to overcome docetaxel resistance in prostate cancer

Recent Progress of Paclitaxel Delivery Systems: Covalent and Noncovalent Approaches

Self-Delivering Prodrug-Nanoassemblies Fabricated by Disulfide Bond Bridged Oleate Prodrug of Docetaxel for Breast Cancer Therapy